IMDX

Insight Molecular Diagnostics Inc

2.83

Oct 23 • 3:59 PM ET -0.01 (-0.35%)

2.83

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Diagnostics & Research USA Micro NASD

Peers: CDNA NTRA BDSX VCYT XGN PSNL TMO CSTL GH MDXH

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	92.61M
Enterprise Value	76.75M
Income	-49.36M
Sales	1.67M
Book/sh	-0.65
Cash/sh	0.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	58
IPO	Dec 30, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	55.46
P/B	-
P/C	5.01
P/FCF	-
EV/EBITDA	-
EV/Sales	45.96
Quick Ratio	1.98
Current Ratio	2.00
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.49
EPS next Y	-0.86
EPS next Q	-0.24
EPS this Y	45.18%
EPS next Y	4.82%
EPS next 5Y	27.84%
EPS past 3/5Y	50.09% 29.01%
Sales past 3/5Y	61.76% 27.24%
EPS Y/Y TTM	57.26%
Sales Y/Y TTM	-60.77%
EPS Q/Q	-0.72%
Sales Q/Q	-53.86%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	-22.05% -32.20%

Insider Own	68.77%
Insider Trans	2.60%
Inst Own	18.80%
Inst Trans	-7.54%
ROA	-123.46%
ROE	-23603.11%
ROIC	-
Gross Margin	-93.38%
Oper. Margin	-2217.90%
Profit Margin	-2955.63%
SMA20	-11.35%
SMA50	-24.45%
SMA200	-41.51%
Trades

Shs Outstand	32.62M
Shs Float	10.22M
Short Float	9.52%
Short Ratio	4.00
Short Interest	0.97M
52W High	8.51 -66.75%
52W Low	2.42 16.94%
Volatility	8.26% 11.47%
ATR (14)	0.33
RSI (14)	36.79
Beta	1.90
Rel Volume	0.17
Avg Volume	243.02K
Volume	42,486

Perf Week	-5.98%
Perf Month	-28.35%
Perf Quarter	-39.79%
Perf Half Y	-24.73%
Perf YTD	-62.27%
Perf Year	-55.92%
Perf 3Y	9.69%
Perf 5Y	-95.85%
Perf 10Y	-96.71%
Recom	1.80
Target Price	8.25
Prev Close	2.84
Price	2.83
Change %	-0.35%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-25	Initiated	Lake Street	Buy	$5
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight	$3.10
Jan-06-22	Resumed	Piper Sandler	Overweight	$3.10
Mar-17-21	Resumed	Needham	Buy	$8
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy	$6
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Nov-30-20	Initiated	BTIG Research	Buy	$5
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$5
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy	$7 → $6
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$2
Jun-02-20	Initiated	Needham	Buy	$4
Feb-13-19	Initiated	Piper Jaffray	Overweight	$6
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

Show Previous Ratings

Oct-14-26 08:00AM	iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch (GlobeNewswire) -6.69%
Oct-12-26 08:00AM	iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings (GlobeNewswire) -5.93%
Sep-02-26 08:00AM	iMDx to Participate in Lake Street 10th Annual Best Ideas Growth "BIG10" Conference (GlobeNewswire)
Aug-11-26 04:05PM	Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing (GlobeNewswire) -7.13%
Aug-10-26 04:39PM	Insight Molecular Diagnostics: Q2 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx (GlobeNewswire)
Aug-04-26 07:00AM	iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference (GlobeNewswire)
Jul-23-26 08:00AM	iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication (GlobeNewswire)
Jul-16-26 03:22PM	Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio (GlobeNewswire)
Jun-29-26 08:00AM	IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper (GlobeNewswire)
Jun-22-26 02:07PM	iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant (GlobeNewswire)
Jun-16-26 04:05PM	Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry (GlobeNewswire) -6.67%
Jun-11-26 04:17PM	IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation (GlobeNewswire) -5.73%
Jun-09-26 04:05PM	iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress (GlobeNewswire)
May-14-26 01:00AM	Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ... (GuruFocus.com) +25.88%
04:17PM	Loading…
May-13-26 04:17PM	Insight Molecular Diagnostics: Q1 Earnings Snapshot (Associated Press)
04:05PM	IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization (GlobeNewswire)
May-06-26 04:05PM	iMDx to Release First Quarter 2026 Results on May 13, 2026 (GlobeNewswire) +9.83%
Apr-14-26 08:00AM	Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay (GlobeNewswire) +20.33%
Mar-26-26 04:27PM	Insight Molecular Diagnostics: Q4 Earnings Snapshot (Associated Press Finance) -13.38%
04:05PM	IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results (GlobeNewswire)
Mar-20-26 08:00AM	iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference (GlobeNewswire) +8.67%
Mar-13-26 08:00AM	Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score (GlobeNewswire)
Mar-03-26 08:00AM	Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission (GlobeNewswire) +10.32%
Feb-11-26 08:00AM	iMDx Announces $26.0 Million Registered Direct Offering (GlobeNewswire) -22.67%
Jan-14-26 09:13AM	Insight congratulated STAR working group on organ health testing paper (TipRanks) -5.26%
Jan-13-26 09:00AM	IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring (GlobeNewswire)
Jan-07-26 04:05PM	iMDx Announces "JPM Week" and "BTIG Snowbird" Conference Participation (GlobeNewswire)
Jan-06-26 08:00AM	iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch (GlobeNewswire)
Jan-05-26 07:00AM	iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion (GlobeNewswire)
12:02PM	Loading…
Nov-12-25 12:02PM	Insight Molecular Diagnostics Inc (IMDX) Q3 2025 Earnings Call Highlights: Pioneering Advances ... (GuruFocus.com) +12.69%
11:15AM	This Biotech Stock Is Up 158% in a Year. Whats Driving It Higher? (Barchart)
Nov-10-25 04:34PM	Insight Molecular Diagnostics: Q3 Earnings Snapshot (Associated Press Finance) +8.97% +10.66%
04:05PM	IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch (GlobeNewswire)
Nov-07-25 07:23AM	Insight Molecular Diagnostics Inc (IMDX) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-03-25 04:05PM	iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week (GlobeNewswire)
Oct-13-25 04:05PM	iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch (GlobeNewswire)
Oct-06-25 07:15AM	iMDx Reports Kidney Transplant Patient Achieved 'Immune Reset' with Novel Therapy and GraftAssure Monitoring (GlobeNewswire)
Sep-24-25 07:05AM	Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando (GlobeNewswire) +8.80%
Sep-08-25 07:15AM	Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database (GlobeNewswire)
07:00AM	IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants (GlobeNewswire)
Aug-26-25 04:05PM	iMDx to Participate in NYC Investment Conferences September 8 - 11 (GlobeNewswire)
Aug-12-25 01:00PM	Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... (GuruFocus.com)
Aug-11-25 06:00PM	Insight Molecular Diagnostics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch (GlobeNewswire)
Aug-04-25 04:05PM	iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference (GlobeNewswire) +8.20% -5.78%
Jul-30-25 04:05PM	IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients (GlobeNewswire) -6.67%
Jul-28-25 04:05PM	iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025 (GlobeNewswire)
Jul-15-25 09:20AM	3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk (Zacks)
Jun-23-25 04:05PM	iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing (GlobeNewswire) -13.68% -5.74%
Jun-17-25 07:00AM	Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville (GlobeNewswire) +17.22%
May-19-25 04:05PM	Medicare Boosts Reimbursement for Oncocyte's Flagship Technology (GlobeNewswire) +5.00%
May-13-25 01:00PM	OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ... (GuruFocus.com)
May-12-25 04:05PM	Oncocyte Reports Q1 2025 Results and Business Progress (GlobeNewswire)
May-07-25 04:10PM	Oncocyte to Release First Quarter 2025 Results on May 12, 2025 (GlobeNewswire)
May-06-25 10:00AM	Best Momentum Stocks to Buy for May 6th (Zacks)
07:41AM	New Strong Buy Stocks for May 6th (Zacks)
Apr-30-25 08:30AM	Oncocyte Provides Positive Update on Clinical Trial Progress (GlobeNewswire)
Apr-29-25 08:30AM	Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity (GlobeNewswire)
Apr-24-25 05:00PM	STAAR Surgical Announces Changes to Board of Directors (Business Wire) +14.92%
06:31AM	New Strong Buy Stocks for April 24th (Zacks)
Apr-07-25 12:00PM	OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-02-25 08:45AM	Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-24-25 06:53PM	OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript (SeekingAlpha) -8.71%
04:05PM	Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts (GlobeNewswire)
Mar-18-25 04:05PM	Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 (GlobeNewswire)
Feb-21-25 12:20AM	OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying Recently (Insider Monkey)
Feb-11-25 08:46AM	OncoCyte prices $29.1M equity offering (TipRanks) +14.49%
08:30AM	Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Feb-10-25 08:30AM	Oncocyte Prices $29.1 Million Equity Offering (GlobeNewswire)
Jan-08-25 08:30AM	Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer (GlobeNewswire)
Jan-06-25 04:05PM	Oncocyte Expands Market Opportunity for VitaGraft Kidney (GlobeNewswire)
Dec-09-24 04:05PM	Oncocyte to Participate in J.P. Morgan Week and Host Investor Meetings (GlobeNewswire)
Dec-04-24 04:15PM	Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study (GlobeNewswire)
Dec-02-24 04:05PM	Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms (GlobeNewswire)
Nov-13-24 02:21AM	OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... (GuruFocus.com)
Nov-12-24 04:05PM	Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 (GlobeNewswire)
Nov-06-24 04:45PM	Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 (GlobeNewswire)
Oct-16-24 04:15PM	Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles (GlobeNewswire)
Oct-08-24 08:30AM	Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial (GlobeNewswire)
Oct-04-24 06:28AM	OncoCyte Secures Funding Through Private Share Sale (TipRanks)
Oct-02-24 06:41PM	Oncocyte Signs Leading Transplant Centers in US and Germany (GlobeNewswire)
06:35PM	Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Aug-20-24 09:00AM	PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology (GlobeNewswire)
Aug-12-24 04:10PM	Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study (GlobeNewswire) -5.13%
Aug-08-24 04:05PM	Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results (GlobeNewswire)
Aug-05-24 04:05PM	Oncocyte Announces August Investor Conferences Participation (GlobeNewswire) +6.27%
Aug-01-24 04:05PM	Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) -5.14%
Jul-11-24 08:00AM	MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in 'Take Advantage of the Moment' Episode (GlobeNewswire)
Jun-24-24 12:41PM	Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move (GlobeNewswire) -6.36%
Jun-17-24 04:05PM	Oncocyte Appoints Andrea James as Chief Financial Officer (GlobeNewswire)
Jun-05-24 07:00AM	OncoCyte's Innovative Approach: Potential in Precision Diagnostics (News Direct)
Jun-03-24 02:13PM	Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study (GlobeNewswire)
May-30-24 04:47PM	Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine (GlobeNewswire)
May-15-24 08:55PM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Oncocyte Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-13-24 08:00AM	Oncocyte to Announce First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 09:19AM	PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 23 '26	Buy	3.50	280,381	982,034	12,395,081	Apr 27 07:08 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 27 '26	Buy	3.64	250,923	913,134	12,684,884	Apr 27 07:08 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 24 '26	Buy	3.53	38,880	137,083	12,433,961	Apr 27 07:08 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 16 '26	Buy	3.45	102,057	351,658	12,033,896	Apr 20 07:24 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 20 '26	Buy	3.88	40,690	157,967	12,114,700	Apr 20 07:24 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 17 '26	Buy	3.57	40,114	143,251	12,074,010	Apr 20 07:24 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Feb 10 '26	Buy	5.75	521,739	2,999,999	11,931,839	Feb 12 07:49 PM
James Andrea S.	Chief Financial Officer	Oct 31 '25	Option Exercise	0.00	50,000	0	201,231	Nov 04 04:05 PM

Insight Molecular Diagnostics, Inc. is a diagnostics technology company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The company was founded in September 2009 and is headquartered in Nashville, TN.

PresidentMr. Joshua Riggs

Chief Financial OfficerMs. Andrea Susan James

VP of AccountingMr. James Liu

Chief Technology OfficerMr. Yuh-Min Chiang Ph.D.

Ph.D.Dr. Ekkehard Schutz M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMDX

Insight Molecular Diagnostics Inc

Upgrade your Finviz experience